A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早前的研究表明人的血液中蛋白含，其发展成心脏病的可能性。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其中,在功能蛋白质组领域内,疾病蛋白质组学在医学和生物药方面具有发现新分子药靶、生物标志物的巨大的潜力。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部分对视神经脊髓炎，多发性硬正常人的血清进行NMO-IgG测定，判断NMO-IgG是否能作为鉴别视神经脊髓炎，多发性硬的一项实验室依据。

A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早前的研究表明人的血液中蛋白含量越高，其发展成心脏病的可能性越高。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其中,在功能蛋白质组领,病蛋白质组学在医学和药方面具有发现新分子药靶、志的巨大的潜力。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部分对视神经脊髓炎，多发性硬化以及正常人的血清进行NMO-IgG测定，判断NMO-IgG是否能作为鉴别视神经脊髓炎，多发性硬化的一项实验室依据。

A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早前的研究表明人的血液中蛋白含量越高，其发展成心脏病的可能性越高。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其中,在功能蛋白质组领域内,疾病蛋白质组学在医学和面具有发现新分子靶、标志的巨大的潜力。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部分对视神经脊髓炎，多发性硬化以及正常人的血清进行NMO-IgG测定，判断NMO-IgG是否能作为鉴别视神经脊髓炎，多发性硬化的一项实验室依据。

A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早前的研究表明人的血液中蛋白含量越高，其发展成心脏病的可能性越高。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其中,在功能蛋白领域内,疾病蛋白在医和生物药方面具有发子药靶、生物标志物的巨大的潜力。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部对视神经脊髓炎，多发性硬化以及正常人的血清进行NMO-IgG测定，判断NMO-IgG是否能作为鉴别视神经脊髓炎，多发性硬化的一项实验室依据。

A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早究表明人血液中蛋白含量越高，其发展成心脏病可能性越高。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其中,在功能蛋白质组领域内,疾病蛋白质组学在医学和生物药方面具有发现新分子药靶、生物标志物巨大潜力。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部分对视神经脊髓炎，多发性硬化以及正常人血清进行NMO-IgG测定，判NMO-IgG能作为鉴别视神经脊髓炎，多发性硬化一项实验室依据。

A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早前研究表明人蛋白含量越高，其发展成心脏病可能性越高。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其,在功能蛋白质组领域内,疾病蛋白质组学在医学和生物药方面具有发现新分子药靶、生物标志物巨大潜力。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部分对视神经脊髓炎，多发性硬化以及正常人进行NMO-IgG测定，判断NMO-IgG是否能作为鉴别视神经脊髓炎，多发性硬化一项实验室依据。

A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早前的研究表明的血液中量越高，其发展成心脏病的可能性越高。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其中,在功能质组领域内,疾病质组学在医学和生物药方面具有发现新分子药靶、生物标志物的巨大的潜力。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部分对视神经脊髓炎，多发性硬化以及的血清进行NMO-IgG测定，判断NMO-IgG是否能作为鉴别视神经脊髓炎，多发性硬化的一项实验室依据。

A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早前研究表明人血液中蛋白含量越高，其发展成心脏病可性越高。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其中,蛋白质组领域内,疾病蛋白质组学医学和生物药方面具有发现新分子药靶、生物标志物巨大。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部分对视神经脊髓炎，多发性硬化以及正常人血清进行NMO-IgG测定，判断NMO-IgG是否作为鉴别视神经脊髓炎，多发性硬化一项实验室依据。

A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早前的研究表明人的血液中蛋白含量越高，其展成心脏病的可能性越高。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其中,功能蛋白质领域内,疾病蛋白质医和生物药方面具有分子药靶、生物标志物的巨大的潜力。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部分对视神经脊髓炎，多性硬化以及正常人的血清进行NMO-IgG测定，判断NMO-IgG是否能作为鉴别视神经脊髓炎，多性硬化的一项实验室依据。